Search Results 1391-1400 of 18157 for monoclonal antibody

1. A Study to Evaluate VSV-hIFNbeta-NIS to Treat Patients with Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, or T-cell Lymphoma - Mayo Clinic

   - Immunotherapy (monoclonal antibodies) =< 4 weeks prior to registration - Experimental agent in case of AML or TCL within 4 half-lives of the last dose of

2. Project 1: Targeting Resistance to T Cell-Directed Therapy in Multiple Myeloma - Mayo Clinic Research

   Both chimeric antigen receptor (CAR)-T cell and bispecific antibody (BsAb) as T cell-directed therapies have yielded impressive clinical responses in people ...

3. A Study To Evaluate The Effectiveness, Safety And Tolerability Of Efgatigimod PH20 SC In Adults With Pemphigus - Mayo Clinic

   Use of any monoclonal antibody (including rituximab or another anti-CD20 biologic) within 6 months before the baseline visit. Known hypersensitivity to any ...

4. Ofatumumab As Primary Therapy Of Chronic Graft Versus Host Disease - Mayo Clinic

   Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy. Uncontrolled infectious complications not ...

5. Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from an adverse event caused by mAbs administered more than 4 ...

6. Clinical trials - Oncology (Medical)

   The purpose of this study is to assess the feasibility and develop procedures for detecting monoclonal proteins via finger pick blood spots and saliva. Data ...

7. A Study of Pembrolizumab Alone or Combined with CC-486 for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer - Mayo Clinic

   Prior treatment with a monoclonal antibody within 4 weeks prior to ... Known or suspected hypersensitivity to monoclonal antibodies; Currently ...

8. Study Of Pembrolizumab (MK-3475) In Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks prior to study Day 1 or who has not recovered from adverse ...

9. A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) - Mayo Clinic

   ... monoclonal antibodies. Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection. Note: Subjects with localized fungal infections ...

10. Publications - Pierre Noel, M.D. - Mayo Clinic

    Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004 Apr 15 ...